Dianabol vs Mazdutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both Dianabol and Mazdutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Dianabol Mazdutide
Weight 300.44 Da 4,563.1 Da
Half-life ~4-6 hours 6-8 days
Chain — 33 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Oxyntomodulin analog with fatty acid conjugation
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Mazdutide
01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
Mazdutide
Start 1.5-3mg weekly, titrate up to 6-9mg based on response / Once weekly injection
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly
T2D management (mild-moderate) 3-4.5mg weekly Once weekly
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Mazdutide
Nausea (mild-moderate, typically improves over time)
Diarrhea
Vomiting
Increased heart rate (5-17 bpm observed)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Research Evidence
Dianabol Mazdutide
Status Well Studied Extensively Studied
References 5 studies 4 studies
Latest 2017 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.